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Summary The aromatase inhibitor, 4-hydroxyandrostenedione (40HA) is an effective treatment for advanced
post-menopausal breast cancer. The clinical and endocrine effects of40HA treatment were studied in five pre-
and perimenopausal women with metastatic breast cancer. Serum oestradiol levels were not significantly
reduced as a result of treatment with 500 mg of40HA by weekly i.m. injections and no patient had a tumour
response. Four patients were subsequently treated with the luteinising hormone releasing hormone (LHRH)
analogue, goserelin, and three had objective responses. The endocrine effects of combined treatment with
goserelin (Zoladex), and 40HA were studied in a further five premenopausal women. Serum oestradiol levels
after treatment with goserelin alone were typical of post-menopausal women. Addition of 40HA led to a
further suppression of oestradiol to within the range observed in post-menopausal patients treated with
40HA. Six patients whose tumours had regressed as a result of goserelin treatment and who subsequently
relapsed were then given combined treatment. Four of the six experienced a second remission. We conclude
that while 40HA alone is unlikely to be a satisfactory treatment for premenopausal patients with advanced
breast cancer, 40HA in conjunction with goserelin leads to profound suppression of oestradiol. The combina-
tion of LHRH analogue and aromatase inhibitor may prove to be a superior treatment to LHRH analogue
alone in these patients.
Removal of oestrogen from breast cancer cells by blockade
of oestrogen synthesis is an effective treatment for hormone-
sensitive advanced breast cancer. Oestrogen synthesis in post-
menopausal women is dependent on aromatisation of
circulating adrenal androgens by peripheral tissues. Amino-
glutethimide (AG), which is a well established treatment for
post-menopausal breast cancer, acts by inhibition of
aromatase (Smith et al., 1978; Santen et al., 1978). Oestrogen
synthesis in non-pregnant premenopausal women (which is
gonadotrophin dependent) occurs mainly in the ovaries,
although at certain times of the menstrual cycle, peripheral
aromatisation contributes significantly to plasma oestrogen
levels (Siiteri et al., 1973; Mendelson et al., 1987). Although
AG inhibits ovarian aromatase, it is not possible to lower
circulating oestrogen levels significantly in premenopausal
women with non-toxic doses of the drug (Santen et al., 1980;
Harris et al., 1982; Wander et al., 1986). 4-Hydroxy-
androstenedione (40HA) is a highly specific aromatase
inhibitor with no other known significant pharmacological
action at therapeutic doses, which has been shown to be an
effective and well tolerated treatment for post-menopausal
breast cancer (Coombes et al., 1984, 1989; Goss et al., 1986).
In vitro, 40HA inhibits aromatase with approximately 60
times the potency of AG (Wing et al., 1985). Unlike AG,
40HA has few toxic side effects (Coombes et al., 1987, 1989).
Ovarian oestrogen synthesis is abolished by surigcal
oophorectomy. Leutinising hormone releasing hormone
(LHRH) analogues such as goserelin inhibit gondadotrophin
release from the pituitary when administered repeatedly
(Dutta et al., 1978). In premenopausal women they have the
effect of suppressing ovarian oestrogen synthesis, and have
been used as an alternative to surgical oophorectomy in the
treatment of advanced breast cancer (Klijn et al., 1982;
Nicholson et al., 1984; Williams et al., 1986). Oestrogen
levels approximate to those in post-menopausal women,
probably because LHRH analogues do not suppress
peripheral aromatisation. It is well established that women
who experience a remission from breast carcinoma as a result
of oophorectomy and who subsequently relapse may
experience a further remission when circulating oestrogen
levels are additionally suppressed by aromatase inhibition
(e.g. Coombes et al., 1989).
We report here on the endocrine and therapeutic effects of
40HA on its own, and in combination with goserelin in
premenopausal women with advanced breast cancer.
Methods
Twelve women with histologically proven metastatic breast
cancer were entered into the study. The median age of
patients on entry was 49 (range 42-52). All patients con-
tinued to menstruate until initiation of goserelin treatment.
Goserelin treatment was started between 2 and 25 months
before entry for those patients who were treated with 40HA
and goserelin in combination.
Goserelin was administered in a dose of 3.6 mg every 4
weeks by subcutaneous injection of a depot formulation
(Zoladex, ICI Pharmaceuticals). 40HA was provided in
ampoules as a sterile microcrystalline formulation (Ciba-
Geigy Pharmaceuticals CGP-32349). The drug was reconsti-
tuted immediately before use and administered by deep in-
tramuscular (i.m.) injection in doses of either 500 mg weekly
or 250 mg every 2 weeks as previously described (Goss et al.,
1986). No other systemic treatments were given within 4
weeks of entry.
Serum oestradiol, follicle stimulating hormone (FSH) and
luteinising hormone (LH) levels were measured by sensitive
and specific radioimmunoassays which have previously been
described in detail (Ferguson et al., 1982; Dowsett et al.,
1987). The gonadotrophin assays have a sensitivity of0.3 and
1 IU 1-1 for FSH and LH respectively. The within and
between assay coefficients of variation are < 10% and
4-11% for both peptides. The oestradiol assay has a sen-
sitivity of 3.5 pmol I', a cross-reactivity with endogenous
steroids of <0.001% and inter- and intraassay coefficients of
variation of <10%.
Full staging investigations were performed on entry, at
intervals of 3-4 months on treatment and on suspicion of
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disease progression, as previously described (Goss et al.,
1986). Patients were seen at least every 4 weeks; clinical
assessment, evaluation of treatment toxicity, measurement of
serum biochemical and haematological parameters and any
further relevant investigations were performed at each visit.
Assessments of response were carried out according to stand-
ard UICC criteria (Hayward et al., 1977). Informed consent
was obtained from all patients before entry.
Results
40HA treatment alone
Five premenopausal women with slowly progressive, non-life-
threatening disease were treated with 40HA at a dose of
500 mg i.m. weekly for between 4 and 19 (median 8) weeks.
Serum oestradiol and gonadotrophin levels, which were
measured on entry and at weekly intervals, are displayed for
up to 9 weeks of treatment in Figures 1 and 2. There was no
consistent fall in oestradiol or compensatory rise in gonadot-
rophin levels in any patient receiving 40HA.
Two of the five patients, aged 50 and 52 respectively
(Figure 1) had markedly variable endocrine profiles, sugges-
tive of perimenopausal behaviour (Sherman et al., 1976)
during 40HA treatment. Both patients initially had post-
menopausal endocrine profiles with low serum oestradiol
levels (< 100 pmol 1-') and elevated gonadotrophin levels
(>20 IU 1-'), although LH levels exceeded FSH levels. Oest-
radiol levels then rose to lie within the premenopausal range
(150-1,000 pmol I') while gonadotrophin levels remained
elevated. Subsequently the gonadotrophin levels also fell to
values expected for premenopausal women (FSH <9 IU 1-',
LH < 14 IU 1' during the follicular and luteal phases of the
menstrual cycle) while oestradiol levels remained in the
premenopausal range. The three remaining patients (ages 42,
45 and 46) had a more typically premenopausal endocrine
profile during 40HA treatment (Figure 2) although elevated
serum gonadotrophin levels accompanied by low
(<100 pmol 1-') oestradiol levels were recorded from two of
the three on one occasion. All five patients continued to
menstruate during 40HA treatment.
All five patients were evaluated for a response to 40HA
treatment. Assessable disease sites were as follows: soft tissue
(four), visceral (one). Disease progressed during treatment in
four patients; the fifth patient remained stable during 8 weeks
of treatment.
Four patients were treated with goserelin on discontinua-
tion of 40HA. Three of the four (including one of the two
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Figure 2 Endocrine profiles of three premenopausal patients
before and during 40HA treatment. Details are the same as in
Figure 1.
perimenopausal patients whose hormone profiles are de-
scribed in detail above) had objective responses as a result of
goserelin treatment. These lasted 9, 12 and 25 months respec-
tively. The other patient was treated with cytotoxic
chemotherapy on termination of the study.
40HA andgoserelin treatment combined
Five patients who were already being treated with goserelin,
and whose disease was either stable or in remission, were
given three injections of 500 mg of40HA at weekly intervals.
Serum oestradiol and gonadotrophin levels were measured
weekly starting 1 week before the first injection of 40HA.
The mean serum oestradiol level of patients on treatment
with goserelin alone was 23.6 ± 4.1 pmol 1-' (mean ± s.e.m.)
which is within the range of values which we have previously
reported for surgically castrate or post-menopausal women
(Dowsett et al., 1987, 1989). Seven days after a single injec-
tion of 40HA, the mean serum oestradiol level was
6.1 ± 0.9 pmol I1', which represents a significant fall
(P <0.001, Student's t test for paired samples). Serum LH
levels which were suppressed as the result of goserelin treat-
ment (mean 1.95 ± 0.21 IU 1-1) were not affected by the
addition of 40HA. Figure 3 shows the oestradiol levels for
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Figure 1 Serial serum oestradiol (top graph), FSH (middle
graph) and LH (bottom graph) in two perimenopausal patients
before treatment, and weekly on treatment with 40HA 500mg
i.m. weekly. Individual patients are represented by the same
symbol in each graph.
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Figure 3 Individual serum oestradiol profiles measured weekly in
five patients before and after the addition of 500 mg 40HA i.m.
weekly to goserelin.
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individual patients measured before 40HA treatment and
weekly on combined treatment. No response assessments
were made in this part of the study.
Six patients who had experienced partial responses as a
result of goserelin treatment and who subsequently relapsed
were treated with the addition of 40HA 250mg i.m. 2-
weekly to goserelin. We have more recently shown 40HA at
this dose produces comparable oestrogen suppression in post-
menopausal women to that induced by 500mg i.m. weekly
(Dowsett et al., 1989). The clinical response rates in post-
menopausal breast cancer are the same for both doses and
the lower dose is significantly better tolerated by patients
(Stein et al., 1990). Three of the patients had previously
participated in the endocrine study of 40HA and goserelin
described above and two had previously been treated with
40HA alone. Four patients experienced objective responses
which lasted for 3 +, 10, 13 and 17 + months respectively as
a result of combined treatment and one patient had disease
stabilisation for 5 months. Disease in the fifth patient con-
tinued to progress. A seventh patient with assessable skin
disease which was unchanged after 2 months of goserelin
treatment was similarly treated with a combination of
goserelin and 40HA; her disease remained stable for a fur-
ther 10 months. The details of these patients are shown in
Table I.
None of the 12 patients treated with 40HA experienced
local or systemic toxicity as a result of their treatment. The
only side-effect resulting from goserelin treatment was hot
flushes.
Discussion
We have failed to find any evidence that 40HA administered
at the maximum tolerated dose of 500 mg i.m. weekly is able
to suppress serum oestradiol in premenopausal women.
40HA is of proven clinical value in post-menopausal
breast cancer, and has been shown to inhibit human ovarian
aromatase in granulosa cell lines (Koos et al., 1985). 40HA
appears to be more effective than AG at inhibiting
aromatisation (Wing et al., 1985) and in inducing regression
of DMBA induced mammary tumours in the premenopausal
rat (Wing et al., 1985). The apparent inability of 40HA (and
of AG) to suppress oestrogen synthesis effectively in
premenopausal women may be due to increases in the release
of pituitary gonadotrophins which overcome the block. AG
treatment of mature female rats (Wing et al., 1985) causes a
rise in LH without a significant fall in oestrogens. In
premenopausal patients treated with AG, gonadotrophin
levels are slightly above the normal range during the luteal
phase of the cycle and the usual rise in oestradiol levels
observed in normal subjects fails to occur, suggesting a par-
tial block (Santen et al., 1980). We have observed no consis-
tent elevation of gonadotrophin levels attributable to 40HA
treatment in our patients. The single observations of elevated
gonadotrophin levels accompanied by low oestradiol levels in
two of our premenopausal patients may represent the
phenomenon described by Santen et al. (1980), but we have
insufficient data to draw firm conclusions.
In contrast to the effects of AG treament on cyclical rats,
oestrogen levels fall and LH levels are unaffected as a result
of 40HA treatment (Wing et al., 1985). The lack of a reflex
rise in LH levels in rats appears to be due to the minor
androgenic activity of 40HA (Wing et al., 1988). In post-
menopausal women, however, in whom androgenic com-
pounds would be expected to reduce gonadotrophin levels,
we have seen no evidence of androgenic activity of 40HA
given by the parenteral route (Goss et al., 1986). It therefore
seems unlikely that the androgenic activity of 40HA is re-
sponsible for the lack of a consistent rise in gonadotrophins
in our patients. The results are more consistent with there
being no significant inhibition of ovarian oestrogen synthesis
by 40HA, probably because 40HA (and AG) are
insufficiently potent to suppress the large amount of
aromatase present in premenopausal women.
If 40HA were effective in premenopausal women, it might
be expected that its activity would most easily be demon-
strated in perimenopausal women whose ovaries should be
more vulnerable to aromatase inhibition. Even in our
perimenopausal patients, there was no reduction in oestradiol
levels on 40HA. Although a higher dose of 40HA could
have been used, in our experience doses in excess of 500 mg
i.m. weekly are associated with an unacceptably high rate of
local toxicity (Goss et al., 1986). Oestradiol suppression has
been observed in premenopausal baboons treated with very
high doses of 40HA (750 mg s.c. daily) for more than one
menstrual cycle (Brodie et al., 1989). No reflex rise in LH
levels was reported in these animals and indeed LH levels
tended to fall with prolonged treatment, suggesting that
40HA may also have significant androgenic activity in
baboons at high doses and that pituitary suppression may
have contributed to the observed oestradiol suppression.
It is unlikely that the perimenopausal behaviour displayed
by two of our patients resulted from 40HA treatment since
both patients initially had post-menopausal oestradiol and
gonadotrophin levels which became premenopausal with con-
tinued 40HA treatment.
As is to be expected from the endocrine data, no clinical
response to 40HA treatment occurred in any of the five
treated patients, although on the basis of subsequent re-
sponse to ovarian suppression with goserelin, three of the
patients had carcinomas that were sensitive to oestrogen
deprivation at the time of the study. The failure of patients
to respond to 40HA treatment is in contrast to the observa-
tions by Wander et al. (1986), who found a 28% response
rate in premenopausal patients treated with AG, and by
Santen et al. (1980), who co-administered AG and very low
dose medroxyprogesterone acetate. Our results are more con-
sistent with the negative clinical findings of Harris et al.
(1982) with AG in premenopausal patients. The discrepancy
in the clinical results of treatment with AG is unexplained. It
has been demonstrated that 40HA suppresses intratumoral
Table I Response to goserelin and to subsequent goserelin and 40HA
Previous Duration of Duration
Age at start endocrine Assessable goserelin Response to of combined
of goserelin treatment disease Response to treatment goserelin treatment
Patient treatment (response) sites goserelin (months) + 40HA (months)
PB 51 Tam (adj: Lung PR 10 PD 4
relapsed Bone
ML 46 Tam (PD) Soft tissue NC 2 NC 10
MPA (NC)
CM 47 Nil Soft tissue PR 12 PR 10
Bone
RM 51 Tam (PD) Soft tissue CR 9 CR 13
40HA (NC)
BD 51 Nil Bone PR 19 PR 17 +
BR 45 Nil Bone PR 24 NC 5
RW 45 40HA (PD) Soft tissue CR 25 PR 3 +
Tam: tamoxifen. MPA: medroxy progesterone acetate.682 R.C. STEIN et al.
aromatase activity in vivo (Reed et al., 1989). The lack of
clinical response to 40HA in our premenopausal patients
suggests that local synthesis of oestrogens may be unimport-
ant in this group of patients although the number of patients
in our study is small (Silva et al., 1989).
Goserelin and other LHRH analogues are known to sup-
press ovarian oestrogen synthesis in premenopausal women,
and have the effect of producing a medically reversible cas-
tration (Klijn et al., 1982; Nicholson et al., 1984; Williams et
al., 1986). The oestradiol levels on treatment in our patients
all fall within the range expected for surgically castrate or
naturally post-menopausal women. Although these data
indicate that LHRH analogues induce complete ovarian sup-
pression, serum oestradiol levels do not fall to zero. The
persistent low levels of oestradiol are almost certainly due to
peripheral conversion of circulating androgens. It seems that
40HA is as effective at inhibiting this conversion in
goserelin-treated premenopausal women as it is in post-
menopausal women. The mean levels of oestradiol while on
goserelin alone (23.6 ± 4.1 pmol I') are a little lower than
those which we have previously reported in untreated post-
menopausal patients (e.g. 31.6 ± 4.3 pmol' 1; Dowsett et al.,
1988). They are, however, similar to those found in buserelin-
treated premenopausal patients, which were also significantly
lower than those in post-menopausal patients (Klijn et al.,
1988). This may be a chance finding but could reflect the
lower degree of peripheral aromatisation in younger women
(Hemsell et al., 1974) or may be the consequence of an effect
of goserelin on ovarian androgen synthesis (Dowsett et al.,
1988). Serum oestradiol levels measured in women treated
with combined therapy were all under 1Opmol 1', which is
close to the lower limits measured in post-menopausal
women treated with 40HA (Dowsett et al., 1987). We have
insufficient data to comment on the relative efficacy of the
two doses of 40HA (500mg i.m. weekly and 250mg i.m.
two-weekly) used in combination with goserelin in this group
of patients, but the situation is likely to be the same as in
post-menopausal women, in whom the two dose levels have
comparable endocrine and clinical activity (Goss et al., 1986;
Dowsett et al., 1987, 1989; Coombes et al., 1989).
The clinical value of combined therapy is demonstrated by
the patients who experienced a second objectively
documented remission, having initially responded to goserelin
treatment and subsequently relapsed. This phenomenon is
well established in women treated initially by surgical
oophorectomy and subsequently with an aromatase inhibitor
(Goss et al., 1986; Coombes et al., 1989). Our demonstration
that aromatase inhibitors can be used successfully in the
same manner combined with LHRH analogues means that
the same range of therapeutic options are open to
premenopausal patients treated with either medical ovarian
suppression or surgical oophorectomy. Furthermore, the
additional oestrogen suppression produced by the combina-
tion of an LHRH analogue and an aromatase inhibitor in
comparison to LHRH analogue treatment alone makes pos-
sible clinical studies which examine whether there is a
'dose-response' relationship of oestrogen suppression in
advanced premenopausal breast cancer. A comparative trial
of an LHRH analogue with and without an aromatase
inhibitor should be conducted to determine whether this
approach to complete oestrogen withdrawal can improve the
outcome of first-line endocrine treatment in premenopausal
breast cancer patients. The inclusion of an aromatase
inhibitor in the combination may have advantages over the
use of tamoxifen since the oestrogen agonist activity of the
latter is greater at low endogenous oestrogen levels and the
combination of tamoxifen and oophorectomy has been
shown to be less effective than oophorectomy alone in animal
tumour models (Nicholson, 1987).
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